[EN] FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRISTIS [FR] DERIVES HETEROARYLE CONDENSES UTILISABLES COMME INHIBITEURS DE KINASE P38, NOTAMMENT DANS LE TRAITEMENT DE POLYARTHRITE RHUMATOIDE
[EN] INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION [FR] COMPOSÉS À SUBSTITUANTS INDAZOLE ET AZAINDAZOLE EN TANT QUE POTENTIATEURS ALLOSTÉRIQUES DE MGLUR4, COMPOSITIONS, ET MÉTHODES DE TRAITEMENT DE DYSFONCTIONNEMENTS NEUROLOGIQUES
Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis
申请人:Angell Martyn Richard
公开号:US20060122221A1
公开(公告)日:2006-06-08
Compounds of formula (I): wherein A is a 5-membered heteroaryl ring are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38, such as rheumatoid arthritis.
Fused heteroaryl derivatives for use as P38 kinase inhibitors
申请人:SmithKline Beecham Corporation
公开号:US07642276B2
公开(公告)日:2010-01-05
Compounds of formula (I): wherein A is a 5-membered heteroaryl ring are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38, such as rheumatoid arthritis.
FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRISTIS
申请人:SMITHKLINE BEECHAM CORPORATION
公开号:EP1531812A1
公开(公告)日:2005-05-25
FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRITIS
申请人:SMITHKLINE BEECHAM CORPORATION
公开号:EP1531812B1
公开(公告)日:2007-06-27
INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
申请人:Vanderbilt University
公开号:US20180022746A1
公开(公告)日:2018-01-25
Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.